PCM
EWTX icon

Prelude Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Prelude Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,584
Closed -$1.03M – 1324
2025
Q4 		$1.03M Sell
41,584
-7,621
-15% -$153K 0.08% 295
2025
Q3 		$798K Buy
49,205
+10,396
+27% +$147K 0.06% 367
2025
Q2 		$509K Sell
38,809
-11,186
-22% -$161K 0.05% 438
2025
Q1 		$1.1M Buy
49,995
+16,831
+51% +$442K 0.08% 291
2024
Q4 		$885K Buy
33,164
+3,871
+13% +$123K 0.06% 420
2024
Q3 		$782K Buy
+29,293
New +$583K 0.05% 456

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prelude Capital Management's EWTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 41,584 shares — an estimated $1.03M sold.

Prelude Capital Management first reported a position in EWTX in Q3 2024 and held it in 6 quarters. The position peaked at $1.1M in Q1 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Prelude Capital Management reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 41,584 Edgewise Therapeutics shares in Q1 2026, an estimated $1.03M.
  • Prelude Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 6 quarters.
  • Prelude Capital Management's Edgewise Therapeutics position peaked at $1.1M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.